Clinical trials in Galdakao – page 8

445 clinical trials in Galdakao, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Galdakao at a glance

445

clinical trials

Research sites1

Quick filters

445 trials in Galdakao

Open in trial search

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treating manic episodes in adults with bipolar I disorder

Investigational

Study of trospium chloride and xanomeline tartrate (KarXT) for treating manic episodes in adults with bipolar I disorder

Investigational

Spain

Participants:18–64 years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Nucresiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Disease risk factor+1

Recruiting

Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

Registered drugNo placebo

Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Amlodipine
Sponsor:Instituto De Investigacion Marques De Valdecilla

Contact Research Centre

HER2 positive breast cancer

Recruiting

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Contact Research Centre

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Amphotericin B
Sponsor:Basilea Pharmaceutica International AG Allschwil

Contact Research Centre

End stage renal disease

Recruiting

Reduced Immunosuppression Therapy Trial for Elderly Kidney Transplant Recipients with End-Stage Renal Disease

Registered drugNo placebo

Reduced Immunosuppression Therapy Trial for Elderly Kidney Transplant Recipients with End-Stage Renal Disease

Registered drugNo placebo

Spain

Participants:65+ years
Substances:Basiliximab
Sponsor:Consorci Mar Parc De Salut De Barcelona

Contact Research Centre

Hypochondroplasia

Recruiting

Study on the Effectiveness and Safety of Infigratinib for Children with Hypochondroplasia and Short Stature

InvestigationalNo placebo

Study on the Effectiveness and Safety of Infigratinib for Children with Hypochondroplasia and Short Stature

InvestigationalNo placebo

Spain

Participants:0–17 years
Substances:Infigratinib
Sponsor:Qed Therapeutics Inc.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Galdakao

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on breast cancer treatments, including trials for HER2-positive and triple-negative variants. Research encompasses innovative therapies for pancreatic adenocarcinoma and colon cancer.

Advanced breast cancer therapies
Neoadjuvant chemotherapy approaches
Metastatic cancer treatments

Multiple trials evaluating novel drug combinations and targeted therapies for improved patient outcomes.

02 Pulmonary Medicine

Comprehensive research into pulmonary fibrosis and respiratory conditions, with studies examining new treatments for COPD and pulmonary embolism management.

Interstitial lung diseases
Progressive pulmonary conditions
Respiratory therapy optimization

Innovative approaches to improve lung function and patient quality of life.

03 Cardiovascular Studies

Investigations into cardiomyopathy prevention and treatment, including trials for acute coronary syndromes and peripheral arterial disease management.

Genetic cardiac conditions
Vascular disease treatments
Antiplatelet therapy optimization

Focus on preventive strategies and improved treatment protocols for heart conditions.

04 Additional Therapeutic Areas

Studies addressing endocrine disorders, including hypothyroidism and its effects. Research on hepatic conditions and smoking cessation therapies.

Liver disease management
Addiction treatment
Hormonal disorders

Diverse therapeutic approaches targeting various medical conditions.

Back to Spain All countries